NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications
September 29, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 29, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting
September 22, 2016 16:01 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System
September 19, 2016 09:28 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Sept. 19, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
August 25, 2016 07:25 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
August 25, 2016 07:18 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
August 11, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions
July 27, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 27, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease
July 26, 2016 08:07 ET
|
NeuroDerm Ltd.
- ND0701 complements the company’s product pipeline for the treatment of advanced Parkinson's disease - - ND0701's proprietary formulation is designed to improve patient convenience by allowing...
NeuroDerm Announces Additions to Management Team
July 06, 2016 11:02 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced...
NeuroDerm to Present at the Cantor Fitzgerald Healthcare Conference on July 13
July 05, 2016 09:04 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...